2D Code Reader Offers Unmatched Data Integrity
Micronic has announced the launch of the new Tracxer Code Reader TS201 — an attractively designed product for reading the 2D Data-Matrix codes of single 24-, 48- and 96-well format sample storage tubes.
Incorporating proprietary 'keyboard wedge' functionality the Tracxer Code Reader TS201 is able to automatically scan and decode any 2D Data-Matrix code making this code reader adaptable to almost any application. Using the keyboard wedge high-end decoding engine ensures that the 2D decoding process is highly reliable thereby producing unmatched data integrity. As a plug-and-play device the Tracxer Code Reader TS201 requires no software installations and is very easy-to-use. Designed to increase your productivity — scanning and decoding a tube takes less than one second. An integral light assists easy and unambiguous sample identification.
The compact (26 cm x 13 cm x 17 cm), robust and stable design of the Tracxer Code Reader TS201 combined with affordable pricing makes it an ideal choice for any laboratory / storage facility requiring high integrity scanning of 2D Data-Matrix coded storage tubes.
For further information or to book a demonstration of the Tracxer Code Reader TS201 please contact Micronic Europe BV (Asia, Africa, Europe and Oceania) now on +31 320 277070/email [email protected] or Micronic America LLC (North, Central and South America) on +1 484 480 3372.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...